Tom Heineman: " ...We presented an abstract detailing pela's ability to induce the expansion of tumor-infiltrating lymphocytes or TILs across multiple cancers, including breast, pancreatic, and colorectal cancer. Pela's ability to expand TIL populations is important because TIL expansion correlates with tumor response. These data further highlight pela's immunotherapeutic mechanism of action and its promise as a backbone immunotherapy for multiple cancer indications.
Taken together, we are extremely excited about the advancements across our pipeline and the growing body of clinical data showcasing pela's broad therapeutic potential."
/#/
" [In] the next study in breast cancer, we are not planning to compete with in Enhertu ,,, We would be coming in and recruiting patients who can either not receive in Enhertu, for example, or who have failed in Enhertu.
And for those groups, the only options really available are traditional chemotherapy for the large -- majority of those patients.
And so actually .... I suspect that there will be a pretty high demand for patients' participation in a study that offers something with clear earlier data that improves upon standard of care chemo, if you see what I'm saying. In other words, I think there'll be plenty of patients who would be looking for a better options than what would otherwise be available. So I would anticipate that the enrollment into the study would be reasonably straightforward. "